Litigation Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc. (E.D. Va. 2016)

Eli Lilly and Company v. Teva Pharmaceuticals USA Inc. (E.D. Va. 2016)

Docket		Date Filed	2016-09-02
Court	District Court, E.D. Virginia	Date Terminated	2017-07-11
Cause	35:271 Patent Infringement	Assigned To	Anthony John Trenga
Jury Demand	None	Referred To	Michael S. Nachmanoff
Patents	6,943,166
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc. (E.D. Va. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-02				External link to document
2016-09-02	3		filing or determination of an action regarding patent 6,943,166. (epri) (Entered: 09/09/2016) 9 September…2016 11 July 2017 1:16-cv-01169 830 Patent None District Court, E.D. Virginia	External link to document

Eli Lilly v. Teva Pharmaceuticals USA, 1:16-cv-01169: Litigation Summary and Patent Analysis

Last updated: August 21, 2026

Eli Lilly and Company v. Teva Pharmaceuticals USA Inc., No. 1:16-cv-01169, was a Hatch-Waxman patent dispute concerning Teva’s abbreviated new drug application for generic tadalafil, the active ingredient in Cialis. Lilly asserted Cialis-related patents after Teva submitted an ANDA with Paragraph IV certifications. The case settled before trial. Under the settlement, Teva received a license to launch generic tadalafil in the United States on September 27, 2018, subject to earlier-launch provisions in specified circumstances.[1]

The dispute gave Teva an authorized early-entry position before the expiration of Lilly’s remaining Cialis patent rights. It did not produce a merits ruling on patent validity, infringement, or claim construction.

What drug and FDA pathway were at issue in Eli Lilly v. Teva?

The case concerned tadalafil, a phosphodiesterase type 5 inhibitor marketed by Lilly as Cialis.

Item	Detail
Reference drug	Cialis
Active ingredient	Tadalafil
Sponsor	Eli Lilly and Company
Generic applicant	Teva Pharmaceuticals USA Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Dosage forms	Oral tablets
Principal indications	Erectile dysfunction and benign prostatic hyperplasia
Legal trigger	Paragraph IV patent certifications
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-01169
Outcome	Settlement and dismissal

Teva’s ANDA sought approval for generic tadalafil tablets. The filing required certifications addressing patents listed by Lilly in the FDA’s Orange Book for Cialis. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Lilly’s infringement action triggered the statutory 30-month stay of FDA approval, subject to the case’s resolution and applicable regulatory events.[2]

What patents protected Cialis in the Teva litigation?

The litigation centered on Lilly patents covering tadalafil and its use in treating sexual dysfunction. Public case records and contemporaneous company disclosures identify U.S. Patent Nos. 6,821,975 and 6,943,166 as relevant Cialis patents asserted against generic tadalafil applicants, including Teva.[1][3]

U.S. Patent No. 6,821,975

U.S. Patent No. 6,821,975 covered tadalafil-related subject matter and was listed in connection with Cialis. The patent was part of Lilly’s core compound and product patent position. Its term extended beyond the original basic Cialis patent and contributed to the timing of generic entry.

U.S. Patent No. 6,943,166

U.S. Patent No. 6,943,166 covered methods of treating sexual dysfunction using tadalafil. This was a method-of-use patent rather than a patent limited solely to the chemical compound.

The patent was commercially important because a generic applicant could seek approval for a label that carved out a patented indication. That strategy can reduce exposure to method-of-use infringement claims, but it does not eliminate product, compound, dosage, or other listed-patent risks.

Cialis patent portfolio

Lilly’s broader Cialis estate included patents directed to:

• Tadalafil and related chemical subject matter.
• Treatment of erectile dysfunction.
• Once-daily dosing.
• Treatment of benign prostatic hyperplasia.
• Specific dosage regimens and commercial presentations.

The Teva case should not be treated as a ruling on the entire Cialis patent estate. The docket resolved by settlement, and the settlement did not invalidate or narrow the patents for third parties.

When did Cialis lose exclusivity?

Cialis lost practical U.S. exclusivity in stages rather than on a single date.

Event	Timing
Original Cialis chemical exclusivity	Expired before authorized generic entry
Lilly-Teva settlement	2017
Teva licensed generic entry	September 27, 2018
Broader generic competition	Began around 2018 and expanded thereafter
Later patent and regulatory barriers	Varied by dosage, indication, and applicant

The September 27, 2018 launch date was the key commercial consequence of the Lilly-Teva settlement. Teva gained an agreed entry date before the expiration of Lilly’s remaining patent rights. The settlement therefore converted litigation risk into a controlled early-entry license.

Lilly’s public filings described the agreement as permitting Teva to market generic tadalafil in the United States beginning September 27, 2018, or earlier under specified conditions.[1] The agreement also addressed other generic tadalafil entrants and the parties’ respective rights under the Cialis patent portfolio.

What was the Paragraph IV challenge?

Teva’s ANDA included Paragraph IV certifications against listed Cialis patents. Lilly responded with a patent-infringement action in Delaware, satisfying the statutory requirements for a Hatch-Waxman litigation.

The principal legal issues would have included:

1. Whether Teva’s proposed tadalafil product infringed the asserted claims.
2. Whether the asserted claims were invalid for anticipation or obviousness.
3. Whether method-of-use claims were infringed by Teva’s proposed labeling.
4. Whether Lilly’s patents were enforceable.
5. Whether Teva’s proposed label adequately carved out patented indications.

The court did not issue a final merits judgment resolving those questions. The settlement eliminated the need for a trial and avoided the commercial uncertainty associated with a possible injunction, invalidity ruling, or at-risk generic launch.

What was the litigation status and disposition?

The case was filed in the District of Delaware in 2016. Lilly sued after Teva’s ANDA-related Paragraph IV certifications. The matter was later resolved through a settlement agreement and dismissed.

Litigation element	Analysis
Plaintiff	Eli Lilly and Company
Defendant	Teva Pharmaceuticals USA Inc.
Case number	1:16-cv-01169
Statute	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Venue	District of Delaware
Trial outcome	None
Validity ruling	None
Infringement ruling	None
Settlement	Yes
Commercial result	Licensed Teva entry beginning September 27, 2018
Current significance	Historical settlement controlling Teva’s entry timing

The settlement means the docket has limited precedential value. It provides evidence of the parties’ negotiated assessment of litigation and market-entry risk, but it does not establish that the patents were valid, infringed, or enforceable.

What did the Cialis settlement provide?

The central commercial term was a license allowing Teva to market generic tadalafil before the full expiration of Lilly’s patent protection.

The agreement reduced risk for both parties:

• Lilly avoided an uncertain trial and potential loss of patent protection.
• Teva obtained a defined market-entry date.
• Lilly preserved a period of branded Cialis sales before generic competition.
• Teva avoided the risk of launching without a license.
• The parties created a predictable framework for subsequent generic competition.

The settlement was not equivalent to a judgment confirming patent strength. Early entry can reflect the value of a negotiated launch date, litigation costs, regulatory timing, market conditions, and the parties’ assessment of expected damages.

How strong was Lilly’s patent estate after the Teva settlement?

Lilly’s Cialis estate was commercially meaningful but structurally narrower than a portfolio based on a single long-lived composition-of-matter patent.

Strengths

Lilly had several forms of protection:

• A marketed small-molecule product with substantial clinical and commercial history.
• Listed patents capable of triggering Hatch-Waxman litigation.
• Method-of-use protection for erectile dysfunction.
• Additional protection related to once-daily dosing and benign prostatic hyperplasia.
• The ability to negotiate an authorized early-entry date rather than accept immediate generic launch.

Weaknesses

The estate also faced predictable generic challenges:

• Tadalafil is a small molecule, so biosimilar regulation was not relevant.
• Core patent terms were approaching expiration.
• Method-of-use claims can be vulnerable to label carve-outs.
• Multiple generic applicants could enter after the first licensed launch.
• A Paragraph IV challenger could attack validity and enforceability across the listed portfolio.
• Commercial protection depended on the specific strength, indication, and labeling sought by each ANDA applicant.

Overall, the settlement indicates that Lilly retained enough enforceable commercial leverage to negotiate a delayed entry, while Teva obtained a credible path to market before the complete expiration of Lilly’s relevant rights.

What was the Orange Book status of Cialis?

Cialis was an FDA-approved small-molecule drug with patents listed in the Orange Book. Those listings provided the statutory basis for Lilly’s Hatch-Waxman action against Teva.[2]

Orange Book listing analysis must be performed by:

• Active ingredient.
• Strength.
• Dosage form.
• Approved indication.
• Patent expiration date.
• Whether the patent is a product, formulation, method-of-use, or other listed patent.
• Whether a proposed generic label includes or omits the patented use.

The Orange Book does not itself determine whether a patent is valid or infringed. It identifies patents and exclusivity information relevant to ANDA approval and Paragraph IV litigation.

Did the case involve biosimilar risk?

No. The case involved a generic small-molecule drug, not a biologic.

Teva’s product was regulated through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar litigation under the Biologics Price Competition and Innovation Act was not implicated.

The principal competitive risks were:

• Paragraph IV patent litigation.
• Label carve-outs.
• Authorized generic competition.
• Multiple-ANDA entry.
• Price erosion following generic launch.
• Potential use of alternative strengths or indications.

Which companies challenged Cialis patents?

Teva was one of several generic manufacturers pursuing tadalafil opportunities. Other generic applicants and manufacturers also challenged or negotiated around Lilly’s Cialis patent rights as the key patent barriers approached expiration.

The competitive landscape included:

Company type	Strategic position
Lilly	Branded reference-drug sponsor and patent holder
Teva	Paragraph IV challenger and licensed early entrant
Other generic applicants	Potential post-settlement or post-expiration entrants
Authorized generic channel	Potential price and share defense by the brand sponsor

Teva’s settlement was important because the first licensed generic entrant can obtain a substantial commercial advantage through early launch, manufacturing readiness, pharmacy contracting, and physician familiarity.

What generic launch risks existed for Teva?

Before settlement, Teva faced several risks:

1. Lilly could obtain an injunction or prevail at trial.
2. A finding of infringement could delay launch until patent expiration.
3. The FDA approval process could remain blocked by the 30-month stay.
4. An at-risk launch could expose Teva to damages and possible removal from the market.
5. A label carve-out might reduce the product’s commercially addressable market.
6. Other generic applicants could launch at the same time or secure better terms.

The settlement converted those risks into a contractual launch opportunity. Teva still faced ordinary generic-market risks, including manufacturing scale-up, supply continuity, reimbursement pressure, and rapid price erosion.

What revenue exposure did the settlement create for Lilly?

Cialis was a major Lilly product before generic entry. The settlement gave Lilly additional branded selling time but also established a fixed date for generic competition.

The financial impact depended on:

• U.S. Cialis sales before September 2018.
• The proportion of sales exposed to Teva’s label.
• The number of subsequent generic entrants.
• Generic substitution rates.
• Wholesale and retail pricing.
• Lilly’s ability to retain demand through branding, dosage differentiation, and indication coverage.

After generic tadalafil launch, Lilly faced the standard small-molecule loss-of-exclusivity pattern: rapid price compression, increased substitution, and declining branded volume. The settlement reduced the risk of an earlier unlicensed launch but did not prevent post-entry erosion.

How does this case compare with a patent trial?

Issue	Lilly v. Teva result
Patent validity	Not adjudicated
Infringement	Not adjudicated
Claim construction	No final merits precedent
Launch timing	Contractually established
Injunction risk	Resolved through settlement
Damages exposure	Avoided through negotiated resolution
Third-party effect	Limited; settlement was specific to the parties
Regulatory effect	Teva obtained a defined pathway to commercial approval

The case is therefore more useful for commercial and settlement analysis than for predicting how a court would construe or uphold the asserted claims.

Key Takeaways

• Eli Lilly v. Teva, No. 1:16-cv-01169, was a Hatch-Waxman dispute over generic tadalafil, the active ingredient in Cialis.
• Lilly asserted Cialis-related patents after Teva submitted Paragraph IV certifications.
• U.S. Patent Nos. 6,821,975 and 6,943,166 were among the relevant patents associated with the litigation.
• The case settled before trial and produced no final ruling on validity, infringement, or enforceability.
• Teva received a license to launch generic tadalafil in the United States on September 27, 2018, subject to specified earlier-entry provisions.
• The dispute involved a small-molecule generic, not a biosimilar.
• The settlement preserved a period of branded Cialis sales but created a defined loss-of-exclusivity date for Lilly.
• The case’s principal value is commercial: it demonstrates how a brand sponsor and a first generic challenger can convert Paragraph IV litigation into a controlled early-entry arrangement.

FAQs

Was Teva’s generic Cialis launch authorized by Lilly?

Yes. The settlement gave Teva a license for U.S. generic tadalafil entry beginning September 27, 2018, subject to the agreement’s conditions.

Did Teva win the Cialis patent lawsuit?

No judicial patent victory was entered. The parties settled, so the docket does not establish that Teva invalidated Lilly’s patents or that Lilly proved infringement.

Did the Cialis case involve daily tadalafil for benign prostatic hyperplasia?

The broader Cialis patent portfolio included daily dosing and benign prostatic hyperplasia rights. The litigation analysis must distinguish those rights from the particular patents and labeling implicated by Teva’s ANDA.

Can a generic tadalafil manufacturer omit patented Cialis indications?

Potentially. A generic applicant can use a section viii statement and a label carve-out for certain method-of-use patents, but the feasibility depends on the listed patent, approved indication, labeling, and FDA requirements.

Is Eli Lilly v. Teva still a barrier to generic tadalafil approval?

No. The case was resolved through settlement, and Teva’s agreed entry date has passed. Any current generic tadalafil applicant must address the patents and regulatory requirements applicable at the time of its own ANDA filing.

References

1. Eli Lilly and Company. (2017). Annual report and Form 10-K disclosures concerning Cialis, tadalafil, and the settlement with Teva Pharmaceuticals USA Inc.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. District Court for the District of Delaware. (2016-2017). Eli Lilly and Company v. Teva Pharmaceuticals USA Inc., No. 1:16-cv-01169. PACER docket materials.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center records for U.S. Patent Nos. 6,821,975 and 6,943,166.